Skip to main content
. 2023 May 10;13:1116937. doi: 10.3389/fonc.2023.1116937

Table 2.0.

Efficacy analysis: best overall response, progression free survival, overall survival for the modified intent-to-treat population (n = 39).

Best Response RECIST v1.1 Disease Control Rate, % Median PFS
Months (Range)
Median OS
Months (Range)
6/9/12 month PFS Rate % 6/9/12- month OS Rate %
3PR, 29SD*, 84.6% 7.8 19.3 54.5/45.9/36.7 86.9/73.3/73.3
6PD (1-25) (9-32)
BORR 7.7% (95% CI: 4.1-13.1) (95% CI:12.8 -)

*One patient with SD had a surgical CR.